Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Endurance RP ( (HK:0575) ).
Endurance RP reported a significantly reduced loss of approximately US$4.48 million for the year ended 31 December 2024, primarily due to operating and R&D expenses. A key development was the submission of a New Drug Application (NDA) by Wanbang Biopharmaceutical to the NMPA in China for Senstend™, with approval expected within 12 months. This could lead to substantial payments to Endurance RP upon approval and commercialization in China. The company also out-licensed Fortacin™ to Kobayashi Pharmaceutical for the Japanese market and made progress on Phase 3 clinical studies in the US. Additionally, Endurance RP is advancing its deep learning aging clock technology through Deep Longevity, aiming to expand its market presence and partnerships.
More about Endurance RP
Endurance RP is a company incorporated in the Cayman Islands, operating in the healthcare and life sciences sectors. It focuses on the development and commercialization of pharmaceutical products, with a particular emphasis on Fortacin™ and Senstend™, and is also involved in deep learning technology for aging clocks through its subsidiary, Deep Longevity.
Technical Sentiment Signal: Buy
Current Market Cap: $13.52M
Learn more about 0575 stock on TipRanks’ Stock Analysis page.